Recipharm, a global CDMO, has developed a new, dedicated manufacturing facility in support of the latest FDA regulatory guidance for non-bacterial beta-lactam medicines. This investment responds to regulatory guidance and to growing customer demand for compliant, dedicated manufacturing services. The final draft guidance published by the FDA requires non-bacterial beta-lactam compounds to be manufactured in a manner that fully prevents cross-contamination with other pharmaceutical products. T...